Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Eli Lilly (NYSE:LLY | LLY Price Prediction) just posted one of the most dominant quarters in Big Pharma history. Revenue grew 48% year over year to $22.974 billion in Q2 2026, Mounjaro alone brought in $9.943 billion, and management raised full-year EPS guidance to $35.50 to $36.50.
Shares closed at $1,156.73, up 8.16% year to date. Modest, given the numbers. So here is the…
